Complete response after docetaxel+pertuzumab+trastuzumab chemotherapy for multimetastatic positive Her 2 breast cancer

Human epidermal growth factor receptor 2 (Her-2)-positive breast cancer has been for a long time an aggressive with poor prognosis disease. However, thanks to targeted therapies, prolonged survival is possible, even in metastatic patients. Nevertheless, while the prognosis has improved, metastatic disease is still not curable. The authors report the original case of a 73-year-old Caucasian woman who presented with a T1a hormonal receptors and Her-2 positive multimetastatic (liver, bones, pleural, adrenal gland, and nodes). The patient began chemotherapy with docetaxel+pertuzumab+trastuzumab regimen with good tolerance, and no grade 3 or more adverse effect. Ca 15-3 level before treatment was high at 729 ng/ml and carcinoembryonic antigen (CEA) was at 1.2 ng/ml. After six cycles of chemotherapy, tomography positron emission scan showed metabolic complete response. Ca 15-3 level decreased to 35 ng/ml and CEA at 0.9 ng/ml. The patient is continuing pertuzumab+trastuzumab. Docetaxel associated to pertuzumab and trastuzumab in metastatic Her2-positive breast cancer is effective and can lead to complete response.

Breast cancer; Her-2 positive; Pertuzumab; Trastuzumab; Docetaxel; Metastases.

[1] Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., et al.: “GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11”. Lyon, France: International Agency for Research on Cancer, 2013.

[2] Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al.: “Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2”. N. Engl. J. Med., 2001, 344, 783.

[3] Macia Escalante S., Rodriguez Lescure A., Pons Sanz V., Martinez Banaclocha N., Guillen Ponce C., Carrato Mena A.: “A patient with breast cancer with hepatic metastases and a complete response to Herceptin as monotherapy”. Clin. Transl. Oncol., 2006, 8, 761.

[4] Witzel I., Muller V., Abenhardt W., Kaufmann M., Schoenegg W., Schneeweis A., Jänicke F.: “Long-term tumor remission under trastuzumab treatment for her2 positive metastatic breast cancer— results from the her-os patient registry. BMC Cancer, 2014, 14, 806.

[5] Swain S.M., Kim S.B., Cortés J., Ro J., Semiglazov V., Campone M., et al.: “Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, doubleblind, placebo-controlled, phase 3 study”. Lancet Oncol., 2013, 14, 461.